Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Humphreys

Orthopaedic Surgery of the Spine Soldotna, AK Medical Doctor

NPI 1144225798 CMS profile 97269

240 Hospital Pl Ste 104, Ste 104, Soldotna, AK 99669

Open in the dashboard

General payments

$198,796

110 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Humphreys of Soldotna, AK is reported in the CMS Open Payments database as having received $198,796 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,030 13
2024 General $44,626 39
2023 General $50,144 16
2022 General $932 7
2021 General $26,123 10
2020 General $22,765 9
2019 General $19,177 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Humphreys
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Steven Humphreys were reported at $35,030. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Steven Humphreys Orthopaedic Surgery of the Spine median Middle half National median
2019 $19,177 $2,106 $337–$18,608 $163
2020 $22,765 $1,213 $156–$15,082 $114
2021 $26,123 $1,834 $271–$15,617 $132
2022 $932 $2,015 $320–$17,036 $149
2023 $50,144 $1,925 $336–$14,599 $160
2024 $44,626 $2,110 $341–$12,483 $164
2025 $35,030 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spineart SA $118,110 15 payments
  2. Medical Investment Advisors LLC $65,815 13 payments
  3. Stryker Corporation $4,134 22 payments
  4. Globus Medical, Inc. $3,912 6 payments
  5. Medtronic, Inc. $2,840 27 payments
  6. Aesculap Implant Systems, LLC $1,372 6 payments
  7. Spineart USA Inc $1,268 4 payments
  8. SI-BONE, Inc. $851 4 payments
  9. Abbott Laboratories $199 9 payments
  10. Osteoremedies, LLC $141 1 payment
  11. Other $155 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $183,897 27 payments
  2. Travel and Lodging $11,497 32 payments
  3. Food and Beverage $2,902 50 payments
  4. Consulting Fee $500 1 payment
Products named General payments · program years 2019–2025
  1. PERLA C $47,478 3 payments
  2. CURE ACP - ANTERIOR CERVICAL PLATE Orthopedic $29,307 2 payments
  3. CURE ACP - ANTERIOR CERVICAL PLATE Devices $24,047 2 payments
  4. CURE ACPv2 - ANTERIOR CERVICAL PLATE Devices $10,344 2 payments
  5. CURE ACPv2 - ANTERIOR CERVICAL PLATE Orthopedic $5,055 2 payments
  6. ExcelsiusGPS Robotic Navigation System $3,912 6 payments
  7. MAZOR X SYSTEM $2,358 17 payments
  8. EVEREST SPINAL SYSTEM $2,242 11 payments
  9. OPEL C - ANTERIOR CERVICAL PLATE $1,396 2 payments
  10. TRITANIUM $1,381 6 payments
  11. Other $4,792 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

54

Median for Orthopedic Surgery: 203

Drug cost

$1,024

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 12 $505
Gabapentin Generic 15 $293
Methocarbamol Generic 15 $161
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$132,298

Medicare's payments for the services billed

Medicare patients

152

Average age 73

Services billed

418

82 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 29%
Depression 26%
Atrial fibrillation 20%
Heart failure 17%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record